Devon researchers believe watercress could treat nappy rash
Researchers from Devon believe healing properties of watercress could lead to new skin treatments.
Similar Posts
Foods to eat, and not eat, to prevent cancer, according to a doctor and nutritionist
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
Johnson & Johnson to settle talc baby powder probe
Containers of Johnson and Johnson baby powder are displayed on a Walgreens shelf on April 05, 2023 in San Anselmo, California. Justin Sullivan | Getty Images Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into whether the company misled patients about the safety of its talc…
Sunak ‘not worried’ about Covid inquiry seeing messages
BBC political editor Chris Mason asked Rishi Sunak if the government was challenging the full release of messages between ministers and officials during the pandemic, to the Covid inquiry, because he was worried about something embarrassing him. The PM said: “Not at all”. He said it was “right that we learn the lessons of Covid”…
States have been eliminating taxes on period products for years.
Packages of Tampax brand tampons on a drugstore shelf in New York on Wednesday, February 10, 2016. Richard Levine | Corbis News | Getty Images Over a lifetime, period products in the U.S. cost a total of around $6,000 per person, according to research published in 2021 — and that’s before tax. In 21 states, a sales tax…
Long Covid: NHS legal action launched by family of girl
The mother of an 11-year-old Aberdeenshire girl claims failings were made by NHS Grampian.
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because…